At ADLM 2026, Thermo Fisher showcased advances in connective tissue disease and multiple myeloma testing. In this exclusive Q&A, Thermo Fisher experts discuss how automation and targeted biomarkers can streamline laboratory workflows and provide more actionable information for clinicians.